• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form EFFECT filed by Gelteq Limited

    9/2/25 12:15:18 AM ET
    $GELS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GELS alert in real time by email
    Notice of Effectiveness
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    Notice of Effectiveness
    Effectiveness Date: August 29, 2025 4:00 P.M.
    Form: F-1
    CIK: 0001920092
    Company Name: Gelteq Ltd
    File Number: 333-288442
    Get the next $GELS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GELS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $GELS
    SEC Filings

    View All

    SEC Form 6-K filed by Gelteq Limited

    6-K - Gelteq Ltd (0001920092) (Filer)

    12/9/25 3:19:42 PM ET
    $GELS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form NT 20-F filed by Gelteq Limited

    NT 20-F - Gelteq Ltd (0001920092) (Filer)

    11/3/25 5:00:53 PM ET
    $GELS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Gelteq Limited

    EFFECT - Gelteq Ltd (0001920092) (Filer)

    9/2/25 12:15:18 AM ET
    $GELS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GELS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Gelteq Announces Positive Preclinical Results Showing Increased Medicinal Cannabinoid Absorption Using Its Oral Gel Delivery Platform

    MELBOURNE, Australia, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Gelteq Limited ("Gelteq" or the "Company"), a clinical and science-based developer of advanced gel-based oral delivery systems, today announced positive results from a recently completed preclinical study which evaluated medicinal cannabinoids delivery through the Company's proprietary oral gel platform. The findings demonstrate that Gelteq's platform significantly enhances the absorption and bioavailability of cannabidiol ("CBD") compared to an existing FDA approved oil-based product. The preliminary results reinforces our platform's potential to change how medicinal cannabis is delivered and experienced by patients. Despite having

    1/13/26 9:00:00 AM ET
    $GELS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gelteq Furthers Asia Presence Through Partnership with Hong Kong Flag Football Program

    MELBOURNE, Australia, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Gelteq Limited ("Gelteq" or the "Company"), a clinical and science-based company specialising in gel-based oral delivery solutions, today announced a new partnership with the Hong Kong Flag Football Program. The partnership will integrate Gelteq's advanced hydration and sports performance formulations into the training and competition programs of the region's men's, women's, and youth national teams. The initiative underscores the increasing interest in high-performance programs throughout the region and builds on the recently announced China-focused sales agreement with Shenzhen Mana Health Management Co. Ltd., which includes minimu

    12/16/25 9:05:00 AM ET
    $GELS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gelteq Signs Three Year Sales Agreement with Shenzhen Mana Health Management Co. Strengthening Gelteq's Nutritional Product Expansion into China

    MELBOURNE, Australia, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Gelteq Limited ("Gelteq" or the "Company"), a clinical and science based innovator in gel based oral delivery technologies, today announced that it has entered into a three year sales agreement with Shenzhen Mana Health Management Co. Ltd. ("Mana") under which Mana will distribute consumer nutritional products within China using Gelteq's proprietary gel formulation. The agreement represents a significant step forward in expanding Gelteq's nutritional product portfolio in China. Mana is a well-established distributor of healthcare and wellness products in China with a strong digital presence and a network of offline retail sales chann

    12/9/25 9:15:00 AM ET
    $GELS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GELS
    Leadership Updates

    Live Leadership Updates

    View All

    Gelteq Appoints Matthew Jones as Head of Sports Performance

    NEW YORK, Jan. 24, 2025 (GLOBE NEWSWIRE) -- Gelteq Limited (NASDAQ:GELS) ("Gelteq" or the "Company"), a global biotechnology company that specializes in the formulation, development, and manufacturing of ingestible gel technology, announced today the appointment of Matthew Jones as Head of Sports Performance. He will oversee the growth, outreach, and customer strategy of Gelteq's sports vertical. "The sports industry is one of a number of key areas that Gelteq's unique formulation can pose a significant improvement to nutrient delivery over traditional methods," said Nathan Givoni, Co-Founder and CEO of Gelteq. "Matthew's pedigree aligns perfectly for this position with his global experie

    1/24/25 8:00:00 AM ET
    $GELS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gelteq Appoints Dr. Paul Wynne as Chief Scientific Officer to Propel Innovative Ingestible Gel Technology

    NEW YORK, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Gelteq Limited (NASDAQ:GELS) ("Gelteq" or the "Company"), a global biotechnology company that specializes in the formulation, development, and manufacturing of ingestible gel technology, announced today the appointment of Dr. Paul Wynne as its Chief Scientific Officer ("CSO").  Gelteq co-founder and CEO Nathan Givoni stated, "We believe Dr. Wynne's distinguished record and expertise in formulation science and drug delivery systems will be instrumental in driving the next phase of Gelteq's product pipeline. Recognized for his collaborative approach and ability to coordinate high-performing teams that drive scientific excellence, Dr. Wynne's ped

    12/19/24 8:30:00 AM ET
    $GELS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gelteq Expands Operations in United States with Appointment of Adam Bendell as President of U.S. Operations to Scale Domestic Business

    NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Gelteq Limited (NASDAQ:GELS) ("Gelteq" or the "Company"), a clinical and science-based company that is focused on developing and commercializing white label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care and other products, announced today that it has expanded its operations in the United States with the appointment of Adam Bendell as President of U.S. Operations.   Gelteq Co-Founder and CEO Nathan Givoni stated, "The appointment of a dedicated U.S.-based President is a critical step in the execution of our growth strategy as we look to scale our operations in the U.S. market. Adam brings not only a wealth of exper

    11/12/24 9:00:00 AM ET
    $GELS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GELS
    Financials

    Live finance-specific insights

    View All

    Gelteq Announces Largest U.S. Customer Increases Initial Order by 50% to Meet Growing Market Demand

    NEW YORK, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Gelteq Limited (NASDAQ:GELS) ("Gelteq" or the "Company"), a clinical and science-based company that is focused on developing and commercializing white label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care, and other products, announces its largest U.S. customer, Healthy Extracts (OTCQB:HYEX), has increased its initial purchase order of Gelteq collagen and Mynus sugar blocker gels by 50%, citing high demand and popularity of the products. Healthy Extracts' platform acquires, develops, patents, markets, and distributes plant-based nutraceuticals that target select high-growth categories within the multibillion-dollar n

    12/2/24 8:30:00 AM ET
    $GELS
    Biotechnology: Pharmaceutical Preparations
    Health Care